rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 6, 2020 (NCT04278131)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- RhodopsinSupplementation
RHO supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07158775 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2025 | Bionic Sight LLC |
| NCT04278131 | Phase 1/Phase 2 (Phase 2) | Feb 6, 2020 | Bionic Sight LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bionic Sight LLC | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1